EQRx

Aumolertinib and Sugemalimab have both shown positive data from Phase III studies in treatment of non-small cell lung cancer and could offer treatment at a fraction of the cost of existing and traditional approaches  EQRx is committed to developing new medicines, offering them at lower prices, reimagining medicine to address one of society’s biggest health […]

...